Recipharm AB, a contract development and manufacturing organization (CDMO), and Medspray BV, a manufacturer of high tech spray nozzles, have completed a previously announced joint venture and established Resyca BV.
 
Resyca will develop and exploit the softmist spray nozzle technology for pharmaceutical applications. This has the potential to eliminate the need for propellants by delivering therapies deep into the lungs more effectively with lower doses as less ends up in the mouth and throat.
 
Commenting on this, Jean-François Hilaire, EVP strategy and global integration, Recipharm AB, said, “We are seeing some excellent traction in this field and have already signed an agreement with several more in the pipeline. The fit with Recipharm’s broader inhalation activities is very clear and is part of our strategy to be the world leading integrated device development and manufacturing provider.”
 
Han van Egmond, CEO of Medspray, added, “Our partnership with Recipharm cements the exciting opportunities we see for the softmist spray nozzle technology in pharmaceutical applications. The potential advantages to both patient and environment make a highly compelling case for its adoption.”
 
Recipharm’s investment in Resyca has been made through its subsidiary Recipharm BV. Resyca will operate development facilities in Munich, Germany and spray nozzles will be supplied exclusively from Medspray in the Netherlands.
 
It is envisaged that commercial supply of finished devices will be manufactured and supplied by other Recipharm affiliates including the specialist device manufacturing capabilities located in King’s Lynn, UK. Additionally, Recipharm will receive an exclusive license to offer its customers the development and manufacturing of syringe-based devices using the softmist nozzle technology. Such devices will be marketed by Recipharm under the brand “Bespak by Recipharm.”